Last reviewed · How we verify
HER2-specific T cells
At a glance
| Generic name | HER2-specific T cells |
|---|---|
| Also known as | Dosing Schedules 1, 2, and 3 |
| Sponsor | Baylor College of Medicine |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- HER2-specific Chimeric Antigen Receptor (CAR) T Cells for Children With Ependymoma (PHASE1)
- A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ (PHASE1)
- TRAIL-R2 and HER2 Bi-Specific Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Metastatic Breast Cancer (PHASE1)
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (PHASE1)
- Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) (PHASE2)
- Memory-Enriched T Cells in Treating Patients With Recurrent or Refractory Grade III-IV Glioma (PHASE1)
- Gene Therapy for HER-Positive Cancer (SENTRY-HER2) (PHASE1, PHASE2)
- Her2 Chimeric Antigen Receptor Expressing T Cells in Advanced Sarcoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HER2-specific T cells CI brief — competitive landscape report
- HER2-specific T cells updates RSS · CI watch RSS
- Baylor College of Medicine portfolio CI